Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Contin

Showing results (11-20 of 72) with videos related to

Pageof 8
Sort By:
Therapeutic Drug Monitoring|December 22, 1999
Effect of felbamate on clobazam and its metabolite kinetics in patients with epilepsyM Contin, R Riva, F Albani, et al.
Clinical Neuropharmacology|December 1, 1992
No effect of chronic bromocriptine therapy on levodopa pharmacokinetics in patients with Parkinson's diseaseM Contin, R Riva, P Martinelli, et al.
European Journal of Clinical Pharmacology|January 1, 1991
Effect of age on the pharmacokinetics of oral levodopa in patients with Parkinson's diseaseM Contin, R Riva, P Martinelli, et al.
Epilepsy Research|September 28, 2011
Levetiracetam clinical pharmacokinetics in elderly and very elderly patients with epilepsyM Contin, S Mohamed, F Albani, et al.
Clinical Neuropharmacology|October 23, 1997
Relationship between levodopa concentration, dyskinesias, and motor effect in parkinsonian patients: a 3-year follow-up studyM Contin, R Riva, P Martinelli, et al.
Annals of Neurology|November 15, 2001
Pharmacodynamic modeling of oral levodopa in Parkinson's diseaseM Contin, R Riva, F Albani, et al.
European Journal of Clinical Pharmacology|January 1, 1986
Altered serum protein binding of carbamazepine in disease states associated with an increased alpha 1-acid glycoprotein concentrationA Baruzzi, M Contin, E Perucca, et al.
International Journal of Clinical Pharmacology, Therapy, and Toxicology|May 1, 1985
Propranolol plasma binding and serum lipids during chronic therapy in migraine patientsF Albani, R Riva, P Cortelli, et al.
Clinical Neuropharmacology|February 1, 1989
Increased dosage of carbidopa in parkinsonian patients on low carbidopa-levodopa regimen. Effect on levodopa bioavailabilityM Contin, R Riva, P Martinelli, et al.
European Journal of Clinical Pharmacology|August 11, 1998
Effect of meal timing on the kinetic-dynamic profile of levodopa/carbidopa controlled release [corrected] in parkinsonian patientsM Contin, R Riva, P Martinelli, et al.
Pageof 8

Showing results (11-20 of 72) with videos related to

Sort By:
Pageof 8
Therapeutic Drug Monitoring|December 22, 1999
Effect of felbamate on clobazam and its metabolite kinetics in patients with epilepsyM Contin, R Riva, F Albani, et al.
Clinical Neuropharmacology|December 1, 1992
No effect of chronic bromocriptine therapy on levodopa pharmacokinetics in patients with Parkinson's diseaseM Contin, R Riva, P Martinelli, et al.
European Journal of Clinical Pharmacology|January 1, 1991
Effect of age on the pharmacokinetics of oral levodopa in patients with Parkinson's diseaseM Contin, R Riva, P Martinelli, et al.
Epilepsy Research|September 28, 2011
Levetiracetam clinical pharmacokinetics in elderly and very elderly patients with epilepsyM Contin, S Mohamed, F Albani, et al.
Clinical Neuropharmacology|October 23, 1997
Relationship between levodopa concentration, dyskinesias, and motor effect in parkinsonian patients: a 3-year follow-up studyM Contin, R Riva, P Martinelli, et al.
Annals of Neurology|November 15, 2001
Pharmacodynamic modeling of oral levodopa in Parkinson's diseaseM Contin, R Riva, F Albani, et al.
European Journal of Clinical Pharmacology|January 1, 1986
Altered serum protein binding of carbamazepine in disease states associated with an increased alpha 1-acid glycoprotein concentrationA Baruzzi, M Contin, E Perucca, et al.
International Journal of Clinical Pharmacology, Therapy, and Toxicology|May 1, 1985
Propranolol plasma binding and serum lipids during chronic therapy in migraine patientsF Albani, R Riva, P Cortelli, et al.
Clinical Neuropharmacology|February 1, 1989
Increased dosage of carbidopa in parkinsonian patients on low carbidopa-levodopa regimen. Effect on levodopa bioavailabilityM Contin, R Riva, P Martinelli, et al.
European Journal of Clinical Pharmacology|August 11, 1998
Effect of meal timing on the kinetic-dynamic profile of levodopa/carbidopa controlled release [corrected] in parkinsonian patientsM Contin, R Riva, P Martinelli, et al.
Pageof 8